Danish company Samplix has launched its comprehensive service program to grant any laboratory access to the advantages of Xdrop™ technology. By partnering with the Samplix Service Team, researchers can leverage the unique Xdrop™ approach to address complex genomic questions, including gap closing, sequencing of repeat elements, detecting viral insertion sites, revealing unintended CRISPR edits, and more.
Xdrop™ is Samplix’s proprietary technology to enrich genomic regions longer than 100 kb from as little as 1 ng human genomic DNA and with single-molecule resolution. Unlike other target enrichment methods, Xdrop™ requires knowledge of only a short sequence within or flanking the target region for efficient target selection. Following targeted selection, multiple displacement amplification is applied to single DNA molecules compartmentalized in droplets. This ensures unbiased amplification of large DNA fragments that are representative of the target variation in the original sample. The output is ready for any short-read or long-read sequencing platform.
Commenting on the service, Henrik Pfundheller, VP Commercial Operations, said: “Our services program is designed to expertly manage workflow points that impact project success. We have regular customer consultations to establish clear research objectives and thus, secure the right experimental setup and sample quality strategy.”
The complete workflow is managed by an expert team of scientists and lab technicians with more than 10 years of experience in international genomics services, handling of precious sample types, project logistics, and dedicated customer care. Upon request, Samplix Services also performs and analyses long-read or short-read sequencing. Every step, including data processing and analysis, if requested, is carefully documented and discussed in a closing consultation.
“Whatever the reason behind a service request," added Pfundheller, “our team overcomes any challenge our customers experience, whether it relates to exploring a new application, getting help in tackling a difficult sequence, or just gaining access to the right equipment."
For more information, visit: www.samplix.com/services
Read more

The ClearLLab 10C system for the clinical flow cytometry lab includes the first 10-colour CE-IVD panels of immunophenotyping reagents for both lymphoid and myeloid lineages. The tubes utilize DURA Innovations dry reagent technology for the panels, which requires no refrigeration. Alongside the panels, the integrated ClearLLab 10C system comprises ClearLLab Control Cells – a liquid preparation of stabilized human erythrocytes and leukocytes (lymphocytes monocytes and granulocytes) – the first application-specific IVD control cells for L&L immunophenotyping as part of a validated system.  ClearLLab Control Cells include assay values for the 27 markers currently available on the four ClearLLab10C panels, available for both normal and abnormal controls. New ClearLLab Compensation Beads are provided for establishing compensation using the ClearLLab compensation kit, which includes 10 single colour tubes for each compensation setup.  In addition, the ClearLLab 10C system incorporates the company’s new Kaluza C software to streamline and standardize clinical QC reporting to international guidelines.  It delivers high quality results from dry unitized combinations of CD (cluster of differentiation) markers, using Beckman Coulter’s DURA Innovations dry technology.  These pre-formulated antibody combinations help the lab avoid the potential errors of manual antibody cocktail preparation.  The four ClearLLab 10C panels are designed specifically to run on Beckman Coulter’s Navios and Navios EX flow cytometers, with new, advanced Navios compensation setup software.  When using the ClearLLab 10C system, compensation is only required on initial set-up of the application, when daily QC fails, after instrument service as needed, or when switching to a new lot of Flow-Set Pro. With the ClearLLab 10C System, laboratories now have a portfolio of flow cytometric tools – enabling them to provide accurate patient results for L&L analysis in a compliant lab setting, without needing to carry out extensive manual validation, preparation and QC tasks.  ClearLLab 10C is also supported by a unique, training resource, the ClearLLab 10C case book.  This provides 24 diagnostic vignettes giving characteristic findings after flow cytometric analysis, with expert assessment by hematopathologists. Labs can also compare the interpretation of their own findings with the analysis in the casebook. With the ClearLLab 10C System, workflow is reduced to four straightforward, standardized steps – sample processing, sample acquisition, reporting and validation. The reagents can be used with peripheral whole blood (collected in K2EDTA, Acid Citrate Dextrose (ACD) or Heparin), bone marrow (collected in K2EDTA, Acid Citrate Dextrose (ACD) or Heparin) and lymph node specimens.  In 2017, the five- colour ClearLLab Reagents panels were the first pre-formulated, IVD antibody cocktails for leukemia and lymphoma immunophenotyping to be approved by the FDA de novo process for in vitro diagnostic use in the US. The FDA confirmed that they provided ‘consistent results to aid in the diagnoses of these serious cancers’ after evaluating data from a multi-site clinical study (which compared panel results to alternative detection methods).  ClearLLab reagents follow the 2006 Bethesda International Consensus Recommendations on the Flow Cytometric Immunophenotypic Analysis of Hematolymphoid Neoplasia. They are compatible with the World Health Organization (WHO) 2016-revised classification of myeloid neoplasms and acute leukemia. WHO, in collaboration with the European Association for Hematopathology and the Society for Hematopathology, recently made important changes to the classification of these diseases. These included new criteria for the recognition of some previously described neoplasms as well as clarification and refinement of the defining criteria for others.

BECKMAN COULTER LIFE SCIENCES
Read more

Lp-PLA2 (Lipoprotein-associated phospholipase A2) is an inflammatory enzyme expressed in atherosclerotic plaques. It is determined as an additional and vascular specific biomarker to predict risk for cardiovascular disease and stroke.
Guidelines from four major international societies (European Society of Cardiology, American College of Cardiology, American Heart Association and American Society of Endocrinology) recommend measurement of Lp-PLA2 for risk stratification in asymptomatic adults.
The liquid-stable, enzymatic DiaSys test Lp PLA2 FS, which determines the activity of the enzyme Lp-PLA2 in serum and plasma, has been available for many years. The assay covers a wide measuring range up to 2000 U/L, offers outstanding onboard and calibration stability and shows excellent precision at clinical cut-off levels. No significant interferences are observed by endogenous compounds; frequently used drugs for dyslipidemia and atherosclerosis do not affect the test.
As no reference method or material for Lp-PLA2 has been available, DiaSys applied the scientifically proven traceability to the reagent specific molar extinction coefficient of 4 nitrophenol to their parameter Lp-PLA2 FS. By this proceeding, DiaSys Lp-PLA2 FS is directly traceable to the Lp-PLA2 reaction product 4-nitrophenol.
Read more

Shimadzu, a leader in analytical instrumentation, has introduced the new HIC-ESP (Ion Chromatograph) featuring a built-in electrodialytic suppressor. This anion suppressor minimizes band spreading and achieves high sensitivity and reliable performance for the quantitative determination of anions.
The suppressor is rugged, providing stable functionality over long periods of operation. The system’s small footprint requires minimal bench space. HIC-ESP covers a wide range of applications in environmental testing, pharma, chemistry and food science.
The HIC-ESP modular inert flow path system integrates a system controller, degasser, pump, CDD detector with temperature-controlled flow cell, autosampler, slim-line oven and the anion suppressor. The system combines a number of special features providing reliable analytical results: Excellent solvent delivery performance, low carryover, fast injection speed (as low as 10 sec), high sample injection precision and repeatability, precise oven temperature regulation and more.
In addition, the ion chromatography system integrates seamlessly with Shimadzu’s LabSolutions platform. This allows users to easily manage parameter setting for IC analysis, batch analyses, autoshutdown, data processing and report creation. Data integrity is assured with the addition of LabSolutions DB and LabSolutions CS.
For more information, visit: www.shimadzu.eu/ liquid-chromatography/nexera/hicesp
Read more